Also listed under Dermatitis, Hypersensitivity, Immediate, Skin Diseases, Eczematous
ClinicalTrials.gov term: Dermatitis, Atopic
45 trials changed in the last 30 days: 3 stopped, 12 with notable changes, 30 with minor changes only.
Trial status changed: Active, Not Recruiting → Suspended
Organon and CoPhase 3 NCT07265479 Registry history of NCT07265479 on ClinicalTrials.gov (opens the registry)
Trial terminated
Also in this update: Final enrollment: 1 participants — 3% of the 30 planned; Primary completion date changed from estimate of Apr 1, 2027 to Jul 18, 2026
Johns Hopkins UniversityPhase 4 NCT06116526 Registry history of NCT06116526 on ClinicalTrials.gov (opens the registry)
Withdrawn before enrolling
Also in this update: Primary completion pushed from Dec 2026 to Dec 2029; Study completion pushed from Dec 2026 to Jul 20, 2030
Boston Children's HospitalNot applicable NCT03664271 Registry history of NCT03664271 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Jun 1, 2026 to Dec 31, 2026
Also in this update: Study completion pushed from Jun 30, 2026 to Dec 31, 2026
Bio-Thera SolutionsPhase 1/2 NCT06094179 Registry history of NCT06094179 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Mar 1, 2027 to Feb 23, 2029
Also in this update: Study completion pushed from Mar 3, 2028 to Feb 23, 2029
Icahn School of Medicine at Mount SinaiPhase 2 NCT07242638 Registry history of NCT07242638 on ClinicalTrials.gov (opens the registry)
Primary endpoint(s) modified
Also in this update: Results posted: Oct 16, 2026; Trial completed
Eli Lilly and CompanyPhase 3 NCT06280716 Registry history of NCT06280716 on ClinicalTrials.gov (opens the registry)
Enrollment reduced: 2000000 → 1200000 participants
Also in this update: Interventions modified; Trial arms changed: 0 → 6
Tampere UniversityNot specified NCT06330974 Registry history of NCT06330974 on ClinicalTrials.gov (opens the registry)
Recruitment opened
Also in this update: Primary completion pushed from Sep 28, 2027 to Oct 28, 2027
Galderma R&DPhase 3 NCT07762833 Registry history of NCT07762833 on ClinicalTrials.gov (opens the registry)
Recruitment opened
Jiangsu Genscend Biopharmaceutical Co., LtdPhase 3 NCT07386743 Registry history of NCT07386743 on ClinicalTrials.gov (opens the registry)
Recruitment opened
Innovent Biologics (Suzhou) Co. Ltd.Phase 3 NCT07754786 Registry history of NCT07754786 on ClinicalTrials.gov (opens the registry)
Recruitment opened
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.Phase 3 NCT07767253 Registry history of NCT07767253 on ClinicalTrials.gov (opens the registry)
Recruitment opened
Also in this update: Trial sites expanded: 1 → 22 locations
PfizerPhase 3 NCT07783425 Registry history of NCT07783425 on ClinicalTrials.gov (opens the registry)
Recruitment opened
Bionyra PharmaPhase 1 NCT07746817 Registry history of NCT07746817 on ClinicalTrials.gov (opens the registry)
Recruitment opened
Pontificia Universidad Catolica de ChileNot applicable NCT07333378 Registry history of NCT07333378 on ClinicalTrials.gov (opens the registry)
Enrollment increased: 60 → 105 participants
Enveda TherapeuticsPhase 2 NCT07298395 Registry history of NCT07298395 on ClinicalTrials.gov (opens the registry)
Trial completed
Also in this update: Final enrollment: 1935 participants (planned 1700)
Galderma R&DPhase 3 NCT03989206 Registry history of NCT03989206 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Also in this update: Primary and study completion moved earlier from Jul 2030 to Nov 2029
AbbViePhase 3 NCT06461897 Registry history of NCT06461897 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Also in this update: Primary completion pushed from Aug 2026 to Nov 2026; Study completion pushed from Mar 2027 to May 2027
AbbViePhase 3 NCT06389136 Registry history of NCT06389136 on ClinicalTrials.gov (opens the registry)
Trial completed
Eli Lilly and CompanyPhase 4 NCT07006792 Registry history of NCT07006792 on ClinicalTrials.gov (opens the registry)
Trial completed
Jiangsu Genscend Biopharmaceutical Co., LtdPhase 1 NCT07411755 Registry history of NCT07411755 on ClinicalTrials.gov (opens the registry)
Trial completed
NAOS Les LaboratoiresNot applicable NCT06756438 Registry history of NCT06756438 on ClinicalTrials.gov (opens the registry)
Trial completed
AbbVieNot specified NCT05081557 Registry history of NCT05081557 on ClinicalTrials.gov (opens the registry)
Trial completed
NAOS Les LaboratoiresNot applicable NCT06930365 Registry history of NCT06930365 on ClinicalTrials.gov (opens the registry)
Trial completed
Evommune, Inc.Phase 2 NCT07150845 Registry history of NCT07150845 on ClinicalTrials.gov (opens the registry)
Trial completed
Also in this update: Primary completion date changed from estimate of Jan 21, 2027 to Apr 13, 2026; Final enrollment: 12343 participants (planned 3930)
Regeneron PharmaceuticalsNot specified NCT03936335 Registry history of NCT03936335 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
SanofiNot specified NCT06837454 Registry history of NCT06837454 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Also in this update: Final enrollment: 572 participants (planned 900)
SanofiNot specified NCT06039241 Registry history of NCT06039241 on ClinicalTrials.gov (opens the registry)
Completed without a posted recruiting period
Nakhia Impex LLCNot applicable NCT07580911 Registry history of NCT07580911 on ClinicalTrials.gov (opens the registry)
Enrollment reduced: 500 → 450 participants
PfizerPhase 3 NCT06807281 Registry history of NCT06807281 on ClinicalTrials.gov (opens the registry)
Trial completed
Nantes University HospitalPhase 4 NCT05642208 Registry history of NCT05642208 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Daniel KaplanPhase 1 NCT06928246 Registry history of NCT06928246 on ClinicalTrials.gov (opens the registry)
Trial completed
Manara UniversityNot applicable NCT07618234 Registry history of NCT07618234 on ClinicalTrials.gov (opens the registry)
Trial completed
Also in this update: Primary completion date changed from estimate of Oct 2026 to Jul 17, 2025; Final enrollment: 57 participants (planned 42)
University of AlbertaNot applicable NCT07009483 Registry history of NCT07009483 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 3 → 21 locations
PfizerPhase 3 NCT07765888 Registry history of NCT07765888 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 10 → 13 locations
Castle Biosciences IncorporatedNot specified NCT07645820 Registry history of NCT07645820 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 150 → 154 locations
SanofiPhase 3 NCT06241118 Registry history of NCT06241118 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 33 → 42 locations
And 1 more change in the last 30 days
PfizerPhase 2 NCT07216027 Registry history of NCT07216027 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 73 → 78 locations
Apogee Therapeutics, Inc.Phase 2 NCT07003425 Registry history of NCT07003425 on ClinicalTrials.gov (opens the registry)
Trial sites reduced: 68 → 61 locations
Kymera Therapeutics, Inc.Phase 2 NCT07217015 Registry history of NCT07217015 on ClinicalTrials.gov (opens the registry)
Trial sites reduced: 68 → 59 locations
And 1 more change in the last 30 days
UCB Biopharma SRLPhase 2 NCT07277660 Registry history of NCT07277660 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 1 → 5 locations
Regeneron PharmaceuticalsPhase 1 NCT07527923 Registry history of NCT07527923 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 79 → 82 locations
SanofiNot specified NCT07290803 Registry history of NCT07290803 on ClinicalTrials.gov (opens the registry)
Study completion pushed from Mar 30, 2027 to Jul 28, 2027
Regeneron PharmaceuticalsNot specified NCT03428646 Registry history of NCT03428646 on ClinicalTrials.gov (opens the registry)
Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting
The University of New South WalesPhase 2 NCT06584552 Registry history of NCT06584552 on ClinicalTrials.gov (opens the registry)
Changed
Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Active, Not Recruiting
University Hospital, Gentofte, CopenhagenNot applicable NCT06032403 Registry history of NCT06032403 on ClinicalTrials.gov (opens the registry)
Changed
Registry verification sweep
Changed
| First posted | Trial | Sponsor | Phase |
|---|---|---|---|
| 2026-10-09 | NCT07867249 Efficacy and Safety of Cream Containing Fig Extract in Subacute and Chronic Eczematous… | Chulalongkorn University new | |
| 2026-10-02 | NCT07856134 AD Treatment Optimization With Ebglyss in Real-World Practice: A Multicenter Study of… | Forefront Dermatology S.C new | Phase 4 |
| 2026-09-29 | NCT07846813 Evidencing Vibroacoustic Sensing for Inflammatory Skin Disease Monitoring | University of Edinburgh new | |
| 2026-09-25 | NCT07842900 Oral Melatonin as Adjunctive Therapy in Adults With Atopic Dermatitis | Can Tho University of Medicine and Pharmacy new | |
| 2026-09-10 | NCT07813611 Secondary Bacterial Infections and Nasal Colonization in Scabies and Atopic Dermatitis | Istanbul Medeniyet University new | |
| 2026-09-09 | NCT07810777 PRA-216 Atopic Dermatitis Safety and Efficacy Study | Prana Therapies Inc new | Phase 2 |
| 2026-09-04 | NCT07804134 Skin-in-Sight: a Longitudinal Cohort Infrastructure for Standardized Remote Monitoring… | Medisch Spectrum Twente new | |
| 2026-09-02 | NCT07800104 Phase 1 Study of QX-4533 in Healthy Volunteers and Patients With Moderate-to-Severe… | QuantX Biosciences, Inc. new | Phase 1 |
| 2026-08-10 | NCT07754968 Use of Bifidobacterium Bifidum in Formula-Fed Infants With Colic, With or Without Atopic… | University of Roma La Sapienza new | |
| 2026-08-05 | NCT07746817 A Study of BYN-001 in Healthy Adults and in Adults With Moderate to Severe Atopic… | Bionyra Pharma new | Phase 1 |
| Early Phase 1 | 1 | |
| Phase 1 | 30 | |
| Phase 1/2 | 5 | |
| Phase 2 | 64 | |
| Phase 2/3 | 5 | |
| Phase 3 | 51 | |
| Phase 4 | 21 |
Sanofi (14) · Pfizer (13) · AbbVie (9) · National Institute of Allergy and Infectious Diseases (NIAID) (9) · Keymed Biosciences Co.Ltd (5) · University of California, San Francisco (5) · Almirall, S.A. (4) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS (4) · Innovent Biologics (Suzhou) Co. Ltd. (4) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (3)